Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ribi ImmunoChem liposome contract

Executive Summary

Six-month, $50,000 Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases has been awarded to firm to conduct Phase I studies of its proprietary adjuvants in liposome vaccine delivery systems. The project will include formulating the company's adjuvant products with genetically engineered and synthetic subunit antigens into liposomes. Ribi said it will apply for a $500,000 Phase II research grant if the studies are successful.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel